In this article, we will look at the 11 Best 52-Week Low Penny Stocks to Invest In.​On January 14, Eddie Ghabour, co-founder of Key Advisors Group LLC, appeared on a Schwab Network interview to discuss his bullish outlook for small-cap stocks. He told Schwab Network that the data suggests a reduction in core inflation, along with a reduction in energy and housing prices. Ghabour believes that the current market setup favors economically sensitive areas, including the small-caps. He added that inflation is a ...

Fermi Inc. (NASDAQ:FRMI) is among the 11 Newly-Listed NASDAQ Stocks to Buy Now. Fermi Inc. (FRMI) Highlights Progress in its Strategic Partnership with Hyundai Engineering & Construction Co., Ltd. On February 11, 2026, Fermi Inc. (NASDAQ:FRMI), operating as Fermi America, highlighted progress in its strategic partnership with Hyundai Engineering & Construction Co., Ltd. to advance large-scale nuclear construction in the United States. The companies are continuing Front-End Engineering Design work for fou ...

Core Viewpoint - Brighthouse Financial reported quarterly earnings of $3.93 per share, missing the Zacks Consensus Estimate of $5.19 per share, and showing a decline from $5.88 per share a year ago, indicating a significant earnings surprise of -24.31% [1] Financial Performance - The company posted revenues of $2.17 billion for the quarter ended December 2025, which was 2.71% below the Zacks Consensus Estimate and a decrease from $2.27 billion in the same quarter last year [2] - Over the last four quarters, Brighthouse Financial has consistently failed to meet consensus EPS and revenue estimates [2] Stock Performance - Since the beginning of the year, Brighthouse Financial shares have decreased by approximately 1.3%, while the S&P 500 has gained 0.9% [3] - The stock currently holds a Zacks Rank of 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $5.04, with expected revenues of $2.25 billion, and for the current fiscal year, the consensus EPS is $20.56 on revenues of $8.97 billion [7] - The trend of estimate revisions for Brighthouse Financial has been unfavorable leading up to the earnings release [6] Industry Context - The Insurance - Life Insurance industry is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom half of the rankings [8] - Another company in the same industry, Citizens, is expected to report quarterly earnings of $0.08 per share, reflecting a year-over-year increase of 14.3% [9]

Meta Platforms, Inc. (NASDAQ:META) is one of Goldman Sachs’s top growth stock picks. On February 12, the board of directors of Meta Platforms, Inc. (NASDAQ:META) declared a quarterly cash dividend of $0.525 per share for both Class A and Class B common stock. The dividend will be payable on March 26, 2026, to shareholders of record as of March 16, 2026. Meta (META) Strengthens Investor Appeal With Dividend Payout and Platform Expansion Efforts Copyright: antonioguillem / 123RF Stock Photo Earlier, on Fe ...

Core View - CoreWeave (NASDAQ:CRWV) is recognized as a prominent AI stock, receiving a Market Outperform rating from Citizens with a price target of $180.00 [1] Company Overview - CoreWeave is identified as a leading GPU-as-a-Service (GPUaaS) provider, positioned to benefit from increasing demand for AI infrastructure, supported by multi-year contracts and a revenue backlog exceeding $56 billion [2] Market Dynamics - The expansion of the GPUaaS total addressable market is driven by accelerated adoption of generative AI and increased outsourcing by hyperscalers, indicating a favorable market environment for CoreWeave [2] Risks and Challenges - The company faces several risks, including potential pricing pressure, customer concentration issues, and leverage concerns [3] - A class action lawsuit has been filed against CoreWeave and certain executives, alleging securities fraud following significant stock drops related to potential violations of federal securities laws [3] Partnerships and Operations - CoreWeave has been collaborating with multiple partners, including Core Scientific, with a merger agreement announced on July 7, 2025 [4] - The company has claimed to be well-positioned to meet strong demand for AI infrastructure but has been criticized for overstating its capacity and failing to disclose significant data center construction delays [4]

Core Viewpoint - The recent volatility in RJF.N's stock price is primarily driven by concerns over AI tools disrupting the wealth management sector, particularly following the launch of Altruist's AI-driven tax planning tool, Hazel [1] Stock Performance - RJF.N's stock exhibited a volatility of 12.84% over the past week, with a peak price of $174.14 on February 10 and a low of $152.03 on February 12 [2] - On February 10, trading volume surged to $672 million, with a turnover rate of 2.12%, before dropping to $201 million on February 13, with a volume ratio of 0.53 [2] - As of February 13, the stock closed at $158.68, reflecting a cumulative decline of 7.82% over five days [2] Financial Report Analysis - During the earnings call on February 11, RJF.N projected a 6.5% quarter-over-quarter growth in asset management and related management fees for Q1 of fiscal year 2026, while maintaining a target of over 20% for adjusted pre-tax profit margin [3] - The company plans to increase investments in AI technology, expand its financial advisor recruitment, and advance the acquisition and integration of boutique investment bank Greensledge to adapt to industry changes [3] Institutional Perspectives - Analysts have differing views on the impact of AI disruption; Citizens analysts suggest that the sell-off may be an overreaction to short-term sentiment, indicating that AI is more likely to expand rather than completely replace human advisory services [4] - Royal Bank of Canada maintained a "Buy" rating for RJF.N on February 14, raising the target price from $168.2 to $182.16, highlighting the company's long-term growth potential [4]

Core Viewpoint - The stock price of Raymond James Financial (RJF.N) has declined by 2.89% to $154.01 as of February 12, 2026, primarily due to market concerns over AI-driven financial tools potentially replacing traditional financial advisory services [1] Stock Performance - On February 10, 2026, the launch of Altruist's AI-driven tax planning tool, Hazel, led to a collective sell-off in the wealth management sector, causing Raymond James Financial's stock to drop by 8.75% [1] - The stock's decline on February 12 is a continuation of the negative sentiment, with a daily trading volume of approximately $189 million and a price fluctuation of 5.01% [1] - The overall asset management sector saw a decline of 3.40% on February 12, exacerbated by a broader market downturn, with the Nasdaq index falling by 1.41% [2] Institutional Perspectives - During the earnings call on February 11, 2026, Raymond James Financial projected a 6.5% quarter-over-quarter increase in management fees and announced plans to increase investments in AI technology [3] - Some institutions, such as Citizens, believe that the current sell-off may be an overreaction to short-term sentiments, suggesting that AI is more likely to expand rather than completely replace human advisory services [3]

Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern speak daily with leaders and decision makers from Wall Street to Washington and beyond. No other program better positions investors and executives for the trading day. Chapters: 00:00:00 - Bloomberg Surveillance starts 00:04:53 - Julian Emanuel, Evercore ISI 00:31:27 - Sharon Bell, Goldman Sachs 00:40:36 - Rep. French Hill, (R) Arkansas 00:51:38 - Kristen Bitterly, Citi Wealth at Work 01:05:23 - Monica Guerra, Morgan Stanley Wealth Mgmt. 01:18:23 - David ...

分组1 - Lincoln National reported quarterly earnings of $2.21 per share, exceeding the Zacks Consensus Estimate of $1.86 per share, and showing an increase from $1.91 per share a year ago, resulting in an earnings surprise of +18.71% [1] - The company achieved revenues of $4.89 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.96%, and up from $4.63 billion year-over-year [2] - Over the last four quarters, Lincoln National has consistently surpassed consensus EPS estimates, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 11.7% since the beginning of the year, while the S&P 500 has gained 1.4% [3] - The current consensus EPS estimate for the upcoming quarter is $1.72 on revenues of $4.94 billion, and for the current fiscal year, it is $8.01 on revenues of $19.86 billion [7] - The Zacks Industry Rank for Insurance - Life Insurance is in the top 25% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is recognized as one of the top 14 booming stocks to buy currently, with Goldman Sachs upgrading its rating to Buy from Neutral and setting a price target of $67 [1][2] Group 1: Stock Ratings and Price Targets - Goldman Sachs analyst Richard Law upgraded CRNX to Buy from Neutral following positive trial results for atumelnant, which showed a 67% reduction in A4 in Cohort 4, consistent with earlier cohorts [2] - Citizens analyst Jonathan Wolleben slightly reduced the price target for CRNX to $105 from $108 while maintaining an Outperform rating [3] Group 2: Product Performance and Revenue - A survey of American endocrinologists indicated a 'positive early experience' with Crinetics' drug Palsonify for treating acromegaly, supporting a preliminary net product revenue of over $5 million for Q4 [4] - Citizens anticipates that Palsonify will continue to exceed expectations through 2026 [5] Group 3: Analyst Consensus and Market Outlook - Wall Street analysts maintain a bullish outlook on CRNX, with a consensus Strong Buy rating and a one-year average price target of $88.64, indicating an upside potential of 60.14% as of January 12 [5]